Norelgestromin And Ethinly Estradiol Patch
Product Images NDC 69238-1521

Product Visual Gallery

This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Norelgestromin And Ethinly Estradiol (NDC 69238-1521). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Ny Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Where To Put Patch (Norelgestromin And Ethinyl Estradiol Transdermal S 1)

Illustrations showing placement of Norelgestromin and Ethinly Estradiol transdermal patches on various body sites including the upper arm, lower abdomen, buttocks, and upper back/shoulder area.*

FDA Label Image

Figure 5 (Norelgestromin And Ethinyl Estradiol Transdermal S 10)

A line graph showing the concentration of Ethinyl Estradiol (EE) in pg/mL over time (hours) for Norelgestromin and Ethinyl Estradiol transdermal patch. The graph includes data from Cycle 1 Week 1, Cycle 3 Week 1, Cycle 3 Week 2, and Cycle 3 Week 3, illustrating EE concentration changes and steady-state levels across different weeks of treatment.*

FDA Label Image

Figure 6 (Norelgestromin And Ethinyl Estradiol Transdermal S 11)

A line graph comparing serum norelgestromin (NGMN) concentration (ng/mL) over time (hours) between a norelgestromin and ethinyl estradiol transdermal system applied to the buttock and an oral contraceptive with NGMN 250 µg and EE 35 µg. The graph shows NGMN concentration on the y-axis and time in hours on the x-axis, with steady-state data based on day 21 for the oral contraceptive.*

FDA Label Image

Flow Chart (Norelgestromin And Ethinyl Estradiol Transdermal S 12)

A line graph comparing the estrogen concentration (EE concentration in pg/mL) over time (hours) between the Norelgestromin and Ethinyl Estradiol Transdermal System applied to the buttock and oral contraceptives with NGM 250 µg and EE 35 µg. The graph shows concentration profiles from 0 to 240 hours, illustrating differences in steady state and peak levels for the transdermal and oral contraceptive methods.*

FDA Label Image

Calendar (Norelgestromin And Ethinyl Estradiol Transdermal S 13)

An illustration showing a vertical continuum of pregnancy rates, with fewer pregnancies per 100 women per year at the top and more pregnancies at the bottom. It categorizes contraceptive methods by their effectiveness: most effective methods like implants, injections, intrauterine devices, and sterilization are listed near the top; moderately effective methods including birth control pills, skin patch, and vaginal rings with hormones are in the middle; barrier methods such as condoms and diaphragm below them; and least effective or behavioral methods like abstinence during fertile days, spermicide, withdrawal, and no birth control at the bottom.*

FDA Label Image

Patient Information Graph (Norelgestromin And Ethinyl Estradiol Transdermal S 14)

An instructional calendar diagram for Norelgestromin and Ethinly Estradiol transdermal patch use. It depicts a four-week schedule: patches are applied daily on Days 1, 8, and 15 corresponding to Weeks 1, 2, and 3, followed by no patch application during Week 4. The graphic emphasizes the patch-free fourth week.*

FDA Label Image

Figure A (Norelgestromin And Ethinyl Estradiol Transdermal S 15)

A horizontal bar chart showing the number of women with a blood clot per 10,000 woman-years for four groups: Non-CHC user/non-pregnant (1 to 5 cases), CHC user (3 to 12 cases), pregnancy (5 to 20 cases), and postpartum (12 weeks only) (40 to 65 cases). The chart compares these ranges visually with shaded portions indicating lower ranges and unshaded portions indicating higher ranges.*

FDA Label Image

Figure B (Norelgestromin And Ethinyl Estradiol Transdermal S 16)

An instructional illustration showing a pair of hands opening a foil pouch containing a transdermal patch. The pouch is being carefully peeled back to expose the patch inside, demonstrating the proper method to open the packaging for the Norelgestromin and Ethinyl Estradiol transdermal patch.*

FDA Label Image

Where To Put Patch (Norelgestromin And Ethinyl Estradiol Transdermal S 17)

A photograph of a human hand holding a small, square transdermal patch with rounded edges. The patch is beige in color and appears to be flexible, likely corresponding to a Norelgestromin and Ethinly Estradiol transdermal patch for prescription use by Amneal Pharmaceuticals.*

FDA Label Image

Usage Illustration 1 (Norelgestromin And Ethinyl Estradiol Transdermal S 18)

Instructional images demonstrating the application of a Norelgestromin and Ethinly Estradiol transdermal patch. The images show the patch being applied to the upper arm, lower abdomen, buttock, and upper back of a person, illustrating correct placement sites for the contraceptive patch.*

FDA Label Image

Usage Illustration 2 (Norelgestromin And Ethinyl Estradiol Transdermal S 19)

An illustration showing two hands holding a silver foil pouch, one hand appearing to open the pouch, likely demonstrating how to remove a transdermal patch. The image is instructional in style, related to the Norelgestromin and Ethinly Estradiol transdermal patch product.*

FDA Label Image

Usage Illustration 1 (Norelgestromin And Ethinyl Estradiol Transdermal S 2)

An illustration showing hands holding a transdermal patch, likely demonstrating the application process for a medication patch. The patch is rectangular and partially peeled from its backing, suitable for skin application.*

FDA Label Image

Usage Illustration 3 (Norelgestromin And Ethinyl Estradiol Transdermal S 20)

An illustration showing hands applying a Norelgestromin and Ethinly Estradiol transdermal patch to the skin. The image demonstrates proper handling of the contraceptive patch by peeling it from its protective backing before application.*

FDA Label Image

Usage Illustration 4 (Norelgestromin And Ethinyl Estradiol Transdermal S 21)

An instructional illustration showing the proper application of a transdermal patch to the skin of a person's arm. The image focuses on hands placing or adjusting a small rectangular patch on the forearm area.*

FDA Label Image

Pouch (Norelgestromin And Ethinyl Estradiol Transdermal S 22)

Norelgestromin and Ethinyl Estradiol transdermal patch applied on skin, showing a single square patch with a beige adhesive layer. The image emphasizes the patch as the dosage form for this human prescription drug by Amneal Pharmaceuticals NY LLC.*

FDA Label Image

Carton (Norelgestromin And Ethinyl Estradiol Transdermal S 23)

Label for Norelgestromin and Ethinly Estradiol Transdermal System patch, 150/35 mcg per day, by Amneal Pharmaceuticals NY LLC. The label shows usage instructions, storage guidance, and a warning that used patches should not be flushed down the toilet. It indicates this is a 1-week therapy patch for transdermal use only and is prescription only.*

FDA Label Image

Norelgestromin And Ethinyl Estradiol Transdermal S 24

Packaging label for Norelgestromin and Ethinyl Estradiol Transdermal System 150/35 mcg per day patch by Amneal Pharmaceuticals LLC. The label indicates a pack containing 3 transdermal systems and includes directions for patch use, storage instructions, and a note that the product is for transdermal use only and prescription use (Rx only).*

FDA Label Image

Usage Illustration 2 (Norelgestromin And Ethinyl Estradiol Transdermal S 3)

An illustration showing hands applying a Norelgestromin and Ethinly Estradiol transdermal patch to the skin, demonstrating proper patch placement technique for this hormone therapy drug.*

FDA Label Image

Usage Illustration 3 (Norelgestromin And Ethinyl Estradiol Transdermal S 4)

An instructional illustration showing hands applying a transdermal patch onto skin, demonstrating proper placement for patch use.*

FDA Label Image

Usage Illustration 4 (Norelgestromin And Ethinyl Estradiol Transdermal S 5)

Illustrative image showing a person applying a transdermal patch to their lower abdomen. The patch is square and appears white or light in color. The image demonstrates the placement of a medicated patch for drug delivery through the skin.*

FDA Label Image

Figure 2 (Norelgestromin And Ethinyl Estradiol Transdermal S 6)

A horizontal bar chart depicting the range of the number of women with a blood clot per 10,000 woman-years across four groups: Non-CHC users, CHC users, pregnant women, and postpartum women (12 weeks only). The chart shows increasing ranges from Non-CHC users (1 to 5) to postpartum women (40 to 65).*

FDA Label Image

Structural Formula (Norelgestromin And Ethinyl Estradiol Transdermal S 7)

A forest plot chart titled 'Risk of Breast Cancer with Combined Oral Contraceptive Use' showing effect estimates (odds ratios or relative risks) from multiple studies. The studies include NICHD Women's Contraceptive Study 2002, French E3N cohort Study 2005, Shangai Women's Health Study 2009, Nurses' Health Study II 2010, Oxford Family Planning Association Study 2013, and Danish Sex Hormone Register Study 2017. The plot displays point estimates and confidence intervals for both ever use and current use of combined oral contraceptives, with effect estimates ranging roughly from 0.9 to 1.3.*

FDA Label Image

Figure 3 (Norelgestromin And Ethinyl Estradiol Transdermal S 8)

Chemical structure diagram showing the molecular structures of Norelgestromin and Ethinyl Estradiol, the active ingredients in the transdermal patch product. The left structure corresponds to Norelgestromin and the right corresponds to Ethinyl Estradiol.*

FDA Label Image

Figure 4 (Norelgestromin And Ethinyl Estradiol Transdermal S 9)

A line graph depicting NGMN concentration (ng/mL) over time (hours) for Norelgestromin and Ethinly Estradiol transdermal patch across different cycles and weeks. Four series are shown: Cycle 1 Week 1, Cycle 3 Week 1, Cycle 3 Week 2, and Cycle 3 Week 3, illustrating concentration trends over a 240-hour period.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.